FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number: 3235-028										
Estimated average burden										
hours per response	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BJERKHOLT ERIC						2. Issuer Name and Ticker or Trading Symbol CHINOOK THERAPEUTICS, INC. [KDNY]								neck all appl Direct	icable) or r (give title	son(s) to Iss 10% Ov Other (s below)	vner		
	Last) (First) (Middle) C/O CHINOOK THERAPEUTICS, INC. 400 FAIRVIEW AVE. NO., 9TH FLOOR					3. Date of Earliest Transaction (Month/Day/Year) 01/31/2022								Chief Financial Officer					
(Street) SEATTL			98102		4. If								6. I Lin	Individual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	-	(Zip)	-Deriv	ative	Se	curities		auired I)isr	nosed o	of or Re	neficial	ly Owne					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				action	2A. Deemed Execution Date,			Code (Instr. 5)			ed (A) or	5. Amor Securiti Benefic Owned	5. Amount of Securities Beneficially Owned Following		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) or (D)	Price	Transac	Reported Transaction(s) Instr. 3 and 4)			(Instr. 4)			
		7	Гable II - I (uired, Di , options					Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day	ate, T	4. Transactior Code (Instr. 8)				6. Date Exercis Expiration Date (Month/Day/Yea			7. Title an of Securit Underlyin Derivative (Instr. 3 ar	ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	e s ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				c	Code	v	(A) (D)		Date Exercisable			Title	Amount or Number of Shares						
Stock Option (right to buy)	\$12.9	01/31/2022			A		88,000		(1)	0	1/30/2032	Common Stock	88,000	\$0.00	88,000	0	D		
Restricted Stock (RSU) (Common	(2)	01/31/2022			A		22,000		(3)	0	1/31/2025	Common Stock	22,000	\$0.00	22,000	0	D		

Explanation of Responses:

- 1. The stock option vests as to 25% of the total shares on January 31, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to
- 2. Each RSU represents a contingent right to receive one (1) share of the Issuer's Common Stock upon settlement.
- 3. The RSUs vests as to one-third (1/3) of the total restricted stock units in equal annual installments beginning on January 31, 2023, until fully vested, subject to the reporting person's provision of service to the Issuer on each vesting date.

Remarks:

/s/ Kirk Schumacher, Attorney-

02/02/2022

in-Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.